Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced nonsmall cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

被引：46
|
作者：
Cho, B. C. [1 ]
Felip, E. [2 ,3 ]
Spira, A. I. [4 ]
Girard, N. [5 ,6 ]
Lee, J. S. [7 ]
Lee, S. H. [8 ]
Ostapenko, Y. V. [9 ]
Danchaivijitr, P. [10 ]
Liu, B. [11 ]
Alip, A. [12 ]
Korbenfeld, E. P. [13 ]
Dias, J. [14 ]
Sun, T. [15 ]
Martinez, M.
Bauml, J. M. [16 ]
Shreeve, M. [17 ]
Sethi, S. [16 ]
Knoblauch, R. E. [16 ]
Hayashi, H. [18 ]
Lu, S. [19 ]
机构：
[1] Yonsei Univ, Div Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Vall Hebron Inst Oncol, Barcelona, Spain
[4] Virginia Canc Specialists, Fairfax, VA USA
[5] Inst Thorax Curie Montsouris, Inst Curie, Paris, France
[6] UVSQ, Univ Paris Saclay, Versailles, France
[7] Seoul Natl Univ Bundang Hosp, Seongnam, South Korea
[8] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[9] Natl Canc Inst, Kiev, Ukraine
[10] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand
[11] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[12] Univ Malaya Med Ctr, Kuala Lumpur, Malaysia
[13] Hosp Britanico Buenos Aires, Buenos Aires, DF, Argentina
[14] Barretos Canc Hosp, Barretos, Brazil
[15] Janssen R&D, Raritan, NJ USA
[16] Janssen R&D, Spring House, PA USA
[17] Janssen R&D, San Diego, CA USA
[18] Kindai Univ, Dept Med Oncol, Fac Med, Osaka, Japan
[19] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA14
引用
收藏
页码：S1306 / S1306
页数：1
相关论文
共 50 条
  • [21] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
  • [22] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Ying Cheng
    Yong He
    Wei Li
    He-long Zhang
    Qing Zhou
    Buhai Wang
    Chunling Liu
    Andrew Walding
    Matilde Saggese
    Xiangning Huang
    Minhao Fan
    Jia Wang
    Suresh S. Ramalingam
    Targeted Oncology, 2021, 16 : 165 - 176
  • [23] Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
    Felip, E.
    Cho, B. C.
    Gutierrez, V
    Alip, A.
    Besse, B.
    Lu, S.
    Spira, A. I.
    Girard, N.
    Califano, R.
    Gadgeel, S. M.
    Yang, J. C-H.
    Yamamoto, S.
    Azuma, K.
    Kim, Y. J.
    Lee, K. -H.
    Danchaivijitr, P.
    Ferreira, C. G.
    Cheng, Y.
    Sendur, M. A. N.
    Chang, G. -C.
    Wang, C. -C.
    Prabhash, K.
    Shinno, Y.
    Stroyakovskiy, D.
    Paz-Ares, L.
    Rodriguez-Cid, J. R.
    Martin, C.
    Campelo, M. R. G.
    Hayashi, H.
    Nguyen, D.
    Tomasini, P.
    Gottfried, M.
    Dooms, C.
    Passaro, A.
    Schuler, M.
    Gelatti, A. C. Z.
    Owen, S.
    Perdrizet, K.
    Ou, S. -H. I.
    Curtin, J. C.
    Zhang, J.
    Gormley, M.
    Sun, T.
    Panchal, A.
    Ennis, M.
    Fennema, E.
    Bauml, J. M.
    Daksh, M.
    Sethi, S.
    Lee, S. -H.
    ANNALS OF ONCOLOGY, 2024, 35 (09) : 805 - 816
  • [24] cost-effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer
    Zhang, Huahua
    Zheng, Xiaochun
    Zhang, Yandong
    Wang, Jiangfeng
    FUTURE ONCOLOGY, 2024,
  • [25] Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
    Cho, Byoung Chul
    Ahn, Myung-Ju
    Kang, Jin Hyoung
    Soo, Ross A.
    Reungwetwattana, Thanyanan
    Yang, James Chih-Hsin
    Cicin, Irfan
    Kim, Dong-Wan
    Wu, Yi-Long
    Lu, Shun
    Lee, Ki Hyeong
    Pang, Yong-Kek
    Zimina, Anastasia
    Fong, Chin Heng
    Poddubskaya, Elena
    Sezer, Ahmet
    How, Soon Hin
    Danchaivijitr, Pongwut
    Kim, Yukyung
    Lim, Yeji
    An, Taewon
    Lee, Hana
    Byun, Hae Mi
    Zaric, Bojan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4208 - +
  • [26] First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
    Sebastian, Martin
    Schmittel, Alexander
    Reck, Martin
    EUROPEAN RESPIRATORY REVIEW, 2014, 23 (131): : 92 - 105
  • [27] Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Aguiar, Pedro N., Jr.
    Haaland, Benjamin
    Park, Wungki
    Tan, Pui San
    del Giglio, Auro
    Lopes, Gilberto de Lima, Jr.
    JAMA ONCOLOGY, 2018, 4 (08) : 1080 - 1084
  • [28] Amivantamab plus chemotherapy vs chemotherapy as firstline treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study
    Girard, N.
    Park, K.
    Tang, K.
    Cho, B. C.
    Paz-Ares, L.
    Cheng, S.
    Kitazono, S.
    Thiagarajan, M.
    Goldman, J. W.
    Sabari, J. K.
    Sanborn, R. E.
    Mansfield, A. S.
    Hung, J-Y.
    Popat, S.
    Dias, J.
    Bhattacharya, A.
    Agrawal, T.
    Shreeve, M.
    Knoblauch, R. E.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1304 - S1304
  • [29] Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
    Piccirillo, Maria Carmela
    Bonanno, Laura
    Garassino, Marina Chiara
    Esposito, Giovanna
    Dazzi, Claudio
    Cavanna, Luigi
    Burgio, Marco Angelo
    Rosetti, Francesco
    Rizzato, Simona
    Morgillo, Floriana
    Cinieri, Saverio
    Veccia, Antonello
    Papi, Maximilan
    Tonini, Giuseppe
    Gebbia, Vittorio
    Ricciardi, Serena
    Pozzessere, Daniele
    Ferro, Alessandra
    Proto, Claudia
    Costanzo, Raffaele
    D'Arcangelo, Manolo
    Proietto, Manuela
    Gargiulo, Piera
    Di Liello, Raimondo
    Arenare, Laura
    De Marinis, Filippo
    Crino, Lucio
    Ciardiello, Fortunato
    Normanno, Nicola
    Gallo, Ciro
    Perrone, Francesco
    Gridelli, Cesare
    Morabito, Alessandro
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : 1086 - 1097
  • [30] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
12345